Skip to content
AnalystLens

Gartner Annual Report, Year Ended Sep 30, 1999

Filing Date
Filed December 22, 1999
Period End
September 30, 1999
Security
IT
In the record · 2016–202610-K1210-Q338-K108

IT filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 108 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’17Apr ’17
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Material agreement8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed December 22, 1999. Cited figures are marked; the original filing is the authoritative source.

Gartner Group, Inc. (filed under this name; later known as Gartner) reported fiscal 1999 (year ended September 30, 1999) total revenues of $734.2 milliona, up 14% from $642.0 million in 1998.

Growth was led by events revenue (up 54% to $75.6 millionb) and services revenue (up 35% to $149.8 million), while research revenue rose 11% to $479.0 million and other revenues slipped to $29.8 million. Operating income fell 9% to $131.0 million, which includes $30.1 million of other charges tied to the recapitalization and reduction-in-force initiatives. Net income was $88.3 million, or $0.84 per diluted share; excluding other charges and a one-time tax benefit, diluted EPS was $1.02, up 10%.

The year was dominated by the recapitalization that separated the company from IMS Health. Stockholders approved a two-class share structure (Class A and Class B, with Class B electing at least 80% of the board), a special cash dividend of $1.1945c per share totaling about $125.0 million, and a Dutch Auction tender offer that repurchased 15,759,279 shares for roughly $345 million. The company also must repurchase 5,166,691 more shares in the open market by July 2001, and it has indemnified IMS Health against certain tax liabilities.

Funding came from a $500 milliond Chase Manhattan credit agreement, of which $250 million was drawn as a term loan at 7.5%. Balance sheet strength weakened materially as a result: total stockholders' equity fell to $74.5 million from $414.9 million, and long-term debt of $250.0 million was added. Cash and marketable securities declined to $88.9 million.

Cash from operations rose to $128.8 million from $97.8 million. The company reported 3,402 employees and a contract value of $684.6 million at year end, up 15%.

Key Highlights

  1. Total revenues of $734.2 million, up 14%; ongoing revenue excluding GartnerLearning rose 18%.
  2. Net income of $88.3 million, or $0.84 diluted EPS; excluding other charges and a one-time tax benefit, diluted EPS was $1.02, up 10%.
  3. Operating income fell 9% to $131.0 million, including $30.1 million in other charges for recapitalization and reduction-in-force costs.
  4. Recapitalization separated the company from IMS Health, including a $125.0 million special dividend ($1.1945 per share) and a Dutch Auction repurchase of 15,759,279 shares.
  5. Stockholders' equity dropped to $74.5 million from $414.9 million, after $250.0 million of long-term debt was added under a $500 million credit facility.
  6. Cash provided by operations rose to $128.8 million from $97.8 million.
  7. Total contract value reached $684.6 million at September 30, 1999, up 15%; services backlog rose 68% to $71.6 million.

Frequently Asked Questions

  1. What drove revenue growth in fiscal 1999?

    Total revenues rose 14% to $734.2 million. Events revenue increased 54% to $75.6 million, services revenue increased 35% to $149.8 million, and research revenue increased 11% to $479.0 million. Other revenues declined slightly to $29.8 million.

  2. What was the impact of the IMS Health recapitalization on shareholders?

    Stockholders approved a Class A and Class B share structure, and Class B stock elects at least 80% of the board. Shareholders received a special cash dividend of $1.1945 per share, about $125.0 million in total. The company repurchased 15,759,279 shares in a Dutch Auction tender offer and must buy another 5,166,691 shares in the open market by July 2001.

  3. How did the recapitalization affect the company's balance sheet?

    Stockholders' equity fell to $74.5 million from $414.9 million a year earlier, and long-term debt of $250.0 million was recorded. Treasury stock rose to $385.0 million. Cash and marketable securities fell to $88.9 million from $218.7 million.

  4. Why did reported earnings decline compared with the adjusted results?

    Net income was $88.3 million, or $0.84 per diluted share, compared with $88.3 million in 1998 and $0.84 per share. The company said this reflected $30.1 million in other charges and an $8.6 million non-deductible recapitalization cost, partly offset by a $2.5 million one-time tax benefit. Excluding these items, diluted EPS was $1.02.

  5. What risks did management highlight?

    Management cited intense competition from independent providers and internal planning groups, limited barriers to entry, pricing pressure in research products, and the difficulty of hiring qualified IT analysts. It also noted debt service obligations, indemnification risk tied to the IMS Health spinoff, Year 2000 uncertainty, and weaker results in Other International markets, which fell 4% to $50.3 million.